echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > "All-rounder" Cabotini enters platinum-incurable metastatic urethra skin cancer.

    "All-rounder" Cabotini enters platinum-incurable metastatic urethra skin cancer.

    • Last Update: 2020-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Author. Cabozanix is a multikine inhibitor that targets targeting targets such as MET, VEGFR, AXL, and RET, and can also affect the tumor immune microenvironment by reducing inhibitory cells that regulate t-cells and bone marrow sources.
    the drug has been approved for thyroid myelin cancer, advanced kidney cancer and liver cancer.
    recently, a phase II study published in The Lancet Oncology evaluated the therapeutic activity of cabotinib in patients with platinum-treatable metastatic urethra cancer (mUC).
    this is an open-label, single-arm, three-line II trial conducted at the National Cancer Institute.
    the patients in the group were aged 18 years, hetleticly diagnosed rare diseases of urethra or urinary tract tissue, KPS score of 60%, and experienced at least one progression of the disease after platinum-based chemotherapy (platinum refractive).
    queue 1 includes patients with metastatic urinary tract skin cancer, and the disease is measured according to the response evaluation criteria of solid tumor RECIST 1.1.
    there are also two parallel groups of exploratory queues (only in patients with urinary path cancer with bone metastasis and patients with rare diseases of urinary tract histology).
    patients receive cabotinib 60 mg oral, once a day, for 28 days, until the disease progresses or is not tolerated for toxicity. The main endpoint of
    is the objective efficiency (ORR) of queue 1 assessed by the researchers through RECIST.
    evaluate the efficacy of all patients who meet the criteria and receive treatment for at least 8 weeks.
    all patients who have undergone at least one cabotinib treatment are included in the safety analysis.
    study: Median follow-up time was 61.2 months.
    in the main queue, 8 patients (19%) observed objective remission, of which the full response was 1 case.
    19 other patients who were stable (45%).
    median progression-free survival of 3.7 months, 6 months and 12 months of survival rates of 37 per cent and 10 per cent, respectively.
    median total survival of 8.1 months, 6 months and 12 months of total survival rates of 64% and 26%, respectively.
    60% of patients with bone metastasis were observed in the queue.
    in a total of 16 patients with urinary path cancer and bone metastasis (from the main and exploratory queues), the median progression-free survival was 3.9 months and the median total survival was 7.2 months.
    of all 68 patients treated with cabotinib, the most common adverse events were fatigue (9 percent), hypertension (7 percent), proteinuria (6 percent) and hypophoscopy (6 percent). no treatment-related deaths were reported in
    .
    results can be seen, in platinum-difficult metastatic urethra skin cancer and bone metastasis patients, cabotinib has single drug clinical antitumor activity, and usually has good tolerance.
    , cabotinib also has innate and adaptive immunomodulation properties, which provides a theoretical basis for the combination of cabotinib and immunotherapy strategies.
    Cabotinib's achievements 1. First line for kidney cancer: Breaking the dust-covered 10-year record On December 19, 2017, the U.S. Food and Drug Administration (FDA) approved Cabotinib for first-line treatment for patients with moderate and high-risk advanced kidney cancer.
    clinical design: 157 patients with advanced kidney cancer were recruited, using cabotinib (79) or Shoneini (78 people) on the front line.
    60 mg daily dose of cabotinib; schoentinib dose of 50 mg per day, for 4 weeks, for 2 weeks.
    clinical data: Cabotini VS Shinitini, with an efficiency of 46% VS 18%, no progression survival of 8.2 months VS 5.6 months, and, more importantly, a total survival of 30.3 months VS 21.8 months.
    2. Liver Cancer: 5% efficiency, control rate as high as 66%, the U.S. FDA officially approved cabotinib for second-line treatment in patients with advanced liver cancer.
    Clinical design: 41 patients with liver cancer were recruited to be treated with cabotinib at a dose of 100 mg per day, and after three months, the patients who assessed the results and stable continued to be randomized clinically, treated with a placebo or cabotinib, respectively.
    clinical data: At 3 months of evaluation, only 5 patients in 41 patients had significantly reduced their tumors and had an efficiency of 5%;
    , 78 percent of patients had tumors shrinking and 35 percent had a decrease in the AFP indicator.
    . Lung Cancer: For patients with RET and EGFR wild, it is worth expecting that about 1% to 2% of patients with non-small cell lung cancer will have a rearrangement of the RET gene, and these patients may consider cabotinib treatment.
    2016, the authoritative medical journal Lancet-Oncology published the second phase of clinical data for NSCLC patients with CAbotinib for RET rearrangement, recruiting 26 patients with an efficiency of 28%, tumor control rate approaching 100%, and most of the patients' tumors under control.
    . The disease control rates for patients with bone metastasis, prostate cancer and ovarian cancer could reach 76%, 71% and 58%, respectively, while the disease control rates for melanoma, breast and non-small cell lung cancer bone metastasis were 45%, 45% and 40%, respectively.
    in bone metastasis, if the oxytocin is ineffective or resistant, you may consider choosing cabotinib.
    "all-rounder" Cabotinib has shown obvious therapeutic effect in kidney cancer, thyroid cancer, liver cancer, prostate cancer, breast cancer and other solid tumors, with broad-spectrum anti-cancer ability, and with a specific good target drug has a more significant advantage.
    we expect more good news from Cabotini.
    Reference Source: 1. Apolo, Andrea B et al. "Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial." The Lancet. Oncology, S1470-2045 (20) 30202-3. 6 Jul. 2020, doi: 10.1016/S1470-2045 (20)30202-3; Choueiri, T.K., et al., Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of The Poor Or Risk: The Alliance A031203 CABOSUN. J Clin Oncol, 2017. 35 (6): p. 591-597.3. Kelley, R.K., et al., Cabozantinib in hepato carcinoma: results of a phase 2 placebo-ced drandomized sgheundra. Ann Oncol, 2017. 28 (3): p. 528-534.4. Drilon, A., et al., Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-single label, -centre, phase 2, single-arm trial. Lancet Oncol, 2016. 17 (12): p. 1653-1660.5. Neal, J.W., et al., Erlotinib, cabozinib, orerlotinib plus cabozantib as second-line or syll-line treatment of patients with EGFR wild-type non-advanced-small-cell-cell-lung cancer (ECOG-ACRIN 1512: Lancet Oncol, 2016. 17 (12): p. 1661-1671.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.